Nebraska Medicaid GLP-1 Coverage 2026: PA Pathway, Eligibility & Appeals

TL;DR

Nebraska Medicaid (administered by the Nebraska Department of Health and Human Services (DHHS) through the Heritage Health managed-care program with three MCOs — Nebraska Total Care (Centene), UnitedHealthcare Community Plan, and Molina Healthcare of Nebraska) does NOT cover GLP-1 receptor agonists for chronic weight management. The categorical exclusion is anchored in the Nebraska Medicaid Pharmacy Provider Manual § 9.2 (“Drugs prescribed for weight loss are not a covered benefit”).

Three FDA-label-restricted carve-outs are operationalized through bifurcated PA forms (separate forms per indication):

Architectural distinctive features:

• Narrowest Wegovy MACE age window we've documented — ages 45–74 only. Most other states accept adults ≥ 18 meeting FDA-label criteria with no upper bound. Nebraska's 45–74 window mirrors the published enrollment age range of the SELECT cardiovascular outcome trial (Lincoff 2023, NEJM).
• Most restrictive Wegovy MASH gate we've documented — 6-month medically-supervised weight-loss-program completion required before approval. West Virginia and Arkansas require only F2–F3 fibrosis confirmation + specialist consultation.
• HbA1c < 6.5% gate on Wegovy MACE — structurally parallel to West Virginia. T2D patients with established CVD are routed to the T2D-indicated GLP-1 pathway (Ozempic) rather than Wegovy MACE.
• Bifurcated PA forms — Nebraska uses separate per-indication PA forms (Wegovy MACE form, Wegovy MASH form, Zepbound OSA form). Utah uses a unified 11-part PA form; West Virginia combines Wegovy CV+MASH in one document but keeps Zepbound OSA separate.
• Three-MCO Heritage Health architecture with Single PDL — Nebraska Total Care (Centene), UHC, and Molina all follow the same state PDL and PA forms. No MCO formulary deviation. Structurally similar to Mississippi (Gainwell SPBA) but different in coverage posture (MS covers chronic weight management; NE does not).

The 2024 LB907 cycle event: Senator Merv Riepe introduced LB907 in January 2024 to mandate Nebraska Medicaid coverage of FDA-approved anti-obesity medications. The Nebraska DHHS fiscal note projected $42.4 million in annual program cost. The HHS Committee voted to Indefinitely Postpone the bill on April 18, 2024, killing it without a floor vote. This outcome reaffirmed Nebraska's categorical chronic-weight-management exclusion through at least the 2025–2026 legislative cycle and there is no successor bill identified in the 109th Legislature as of May 15, 2026.

Medicaid expansion status: Nebraska voters approved Initiative 427 (Medicaid expansion) by ballot initiative in November 2018 with 53.5% support. After regulatory delays, Nebraska implemented Medicaid expansion effective October 1, 2020 covering adults 19–64 at or below 138% of the federal poverty level. Approximately 90,000 Nebraskans are enrolled through the expansion population (out of a total Nebraska Medicaid population of ~430,000).

Pharmacy benefit architecture:

• PBM: Magellan Rx (rebranded as Prime Therapeutics State Government Solutions in 2024–2025)
• Provider PA help desk: 1-866-244-8554
• Member help desk: 1-877-294-2440
• PA fax: 1-844-879-9132
• Single PDL: applies uniformly across FFS + all 3 Heritage Health MCOs

1. Federal authority: 42 U.S.C. § 1396r-8(d)(2)(A)

The federal Medicaid drug rebate statute at 42 U.S.C. § 1396r-8(d)(2)(A) grants states an optional authority to exclude “Agents when used for anorexia, weight loss, or weight gain” from coverage. Nebraska has exercised this authority — categorically — and has NOT executed a State Plan Amendment carve-back-in for chronic weight management. Three FDA-label-restricted carve-outs (Wegovy MACE, Wegovy MASH, Zepbound OSA) operate at the PBM PA level, not at the State Plan Amendment level.

The Nebraska Medicaid Pharmacy Provider Manual § 9.2 reproduces the federal exclusion at the state regulatory level: “Drugs prescribed for weight loss are not a covered benefit.” This is the regulatory baseline against which the three FDA-label carve-outs operate as exceptions.

2. Wegovy CV/MACE carve-out (ages 45–74)

Per the Nebraska Medicaid Wegovy MACE PA form (verbatim, last reviewed 2025):

1. Patient age 45 to 74 years (inclusive). Patients outside this window cannot use the MACE carve-out.
2. BMI ≥ 27 kg/m².
3. Established cardiovascular disease:
   • Prior myocardial infarction (MI), OR
   • Prior stroke (ischemic or hemorrhagic), OR
   • Symptomatic peripheral arterial disease confirmed by ankle-brachial index (ABI) ≤ 0.9 OR peripheral revascularization procedure OR amputation due to atherosclerotic disease
4. Prescribed by or in consultation with a specialist: cardiology, vascular surgery, or neurology.
5. HbA1c < 6.5% within the last 6 months. Patients with HbA1c ≥ 6.5% are routed to the T2D-indicated GLP-1 PA pathway (Ozempic, which carries an FDA cardiovascular indication for T2D patients).
6. No concurrent GLP-1, GIP, or DPP-4 receptor agonist.
7. Patient attests to behavioral modification: reduced-calorie diet + increased physical activity.

Initial approval: 6 months. Reauthorization (6 months) requires titration to Wegovy 2.4 mg weekly dose, documented ≥ 5% baseline body weight loss after 20 weeks (maintained), and continued guideline-recommended MACE secondary prevention.

2.1 The 45–74 age gate

Nebraska Medicaid is the only state we've reviewed with an explicit upper age limit on Wegovy MACE coverage. The 45–74 window appears to mirror the published enrollment age range of the SELECT cardiovascular outcome trial — Lincoff et al. 2023, NEJM (PMID 37952131) — which enrolled patients 45 years and older with established CVD without diabetes. SELECT's upper enrollment age bound was not explicitly capped at 74, but the trial population skewed heavily toward 50–75 (median age ~62), and Nebraska Medicaid appears to have used the trial's effective enrollment window as the coverage gate.

Operational consequence: patients 75 years and older with established CVD and BMI ≥ 27 cannot use the Nebraska Wegovy MACE carve-out, even when they meet the FDA-label criteria (which have no upper age bound). Appeals on age-denial grounds referencing the FDA-label-no-upper-bound + the SELECT publication for clinical-rationale support are the strongest appeal route, but success is uncertain.

3. Wegovy MASH carve-out (6-month medically-supervised weight-loss-program prerequisite)

Per the Nebraska Medicaid Wegovy MASH PA form (verbatim, last reviewed 2025):

1. Patient age ≥ 18 years.
2. Diagnosis of noncirrhotic MASH with moderate-to-advanced fibrosis (F2–F3) confirmed by:
   • Liver biopsy showing NAFLD activity score ≥ 4 with steatosis, ballooning, and lobular inflammation each > 1, OR
   • Vibration-controlled transient elastography (FibroScan) or magnetic resonance elastography (MRE) consistent with F2 or F3 fibrosis.
3. Prescribed by or in consultation with a gastroenterologist or hepatologist.
4. 6-month medically-supervised weight-loss program completion prior to PA submission. Acceptable program elements: registered dietitian counseling at minimum monthly intervals, BMI tracking, dietary modification documentation, physical activity prescription. Documentation must come from the patient's medical record — not self-attestation.
5. Patient compliant with stable medications for diabetes, dyslipidemia, and hypertension (where applicable).
6. No decompensated cirrhosis.
7. For patients with both T2D and MASH: T2D therapy should be managed with a T2D-indicated GLP-1 receptor agonist at the appropriate dose.
8. No concurrent GLP-1, GIP, or DPP-4 receptor agonist.

Initial approval: 6 months. Reauthorization: 12 months with documented positive clinical response (resolution of steatohepatitis without worsening fibrosis OR at least one stage fibrosis improvement without worsening steatohepatitis).

3.1 The 6-month weight-loss-program prerequisite

Nebraska Medicaid is the only state we've reviewed with a 6-month medically-supervised weight-loss-program completion prerequisite for Wegovy MASH coverage. West Virginia, Arkansas, Utah, Oklahoma, and Iowa accept F2–F3 fibrosis documentation + specialist consultation alone — no preparatory weight-loss program required.

Operational consequence: a patient newly diagnosed with F2–F3 MASH at a gastroenterology consult cannot immediately initiate Wegovy in Nebraska. They must complete 6 months of a documented weight-loss program first — even when the prescribing GI or hepatology team considers immediate initiation clinically optimal. This is structurally significant because the FDA-approved Wegovy MASH label (August 2025 expansion) is intended for patients who have not yet progressed to decompensated cirrhosis — delaying treatment by 6 months for a documentation prerequisite has clinical implications.

Practical guidance: patients pursuing Wegovy MASH in Nebraska should begin the 6-month weight-loss-program documentation at the time of MASH diagnosis — even before the GI consult formally recommends Wegovy — so the program timer is running concurrent with the diagnostic workup. Acceptable program structures include: registered dietitian (RD) counseling in primary care, structured medical weight-loss programs through obesity medicine specialists, hospital-affiliated bariatric programs.

4. Zepbound OSA carve-out (70% PAP adherence)

Per the Nebraska Medicaid Zepbound OSA PA form (verbatim, last revised 07/01/2025):

1. Patient age ≥ 18 years.
2. Moderate-to-severe OSA confirmed by AHI (apnea-hypopnea index), RDI (respiratory disturbance index), or REI (respiratory event index) ≥ 15 on a sleep study within the past 24 months.
3. BMI ≥ 30 kg/m².
4. Prescribed by or in consultation with a sleep medicine specialist.
5. 70% positive airway pressure (PAP) adherence at 4+ hours per night for at least 2 months OR documented PAP intolerance with rationale.
6. No concurrent GLP-1, GIP, or DPP-4 receptor agonist.
7. Pregnancy / breastfeeding excluded.

Initial approval: 6 months. Reauthorization requires documented OSA-symptom improvement (Epworth Sleepiness Scale reduction, partner-reported snoring/apnea-event reduction) AND continued PAP use.

4.1 70% PAP adherence requirement

Nebraska's 70% PAP adherence threshold (at 4+ hours/night for 2+ months) is structurally parallel to Utah's stricter version (70% adherence for the full 6 months). West Virginia requires only CPAP counseling (not failure or adherence), making Nebraska's gate moderately stricter than WV but less strict than UT.

4.2 No T2D step-therapy bridge

Unlike West Virginia, Nebraska does NOT require T2D patients to first fail a preferred T2D GLP-1 receptor agonist before accessing Zepbound OSA. T2D patients can directly pursue Zepbound OSA if they meet the AHI, BMI, PAP adherence, and specialist-consult gates — subject to the no-concurrent-GLP-1 exclusion (which means they need to be off any other GLP-1 first).

5. What Nebraska Medicaid does NOT cover

The Nebraska Medicaid Pharmacy Provider Manual § 9.2 categorical exclusion applies to all FDA-approved anti-obesity medications used for chronic weight management. As of January 2026:

• Wegovy for chronic weight management (non-CV/non-MASH) — NOT covered.
• Zepbound for chronic weight management (non-OSA) — NOT covered.
• Saxenda (liraglutide AOM) — NOT listed on the Single PDL Anti-Obesity Agents class; presumptively non-covered.
• Foundayo (orforglipron, oral GLP-1 AOM) — approved April 1, 2026; NOT yet integrated into the Single PDL. Presumptively non-covered.
• Contrave (naltrexone/bupropion), Qsymia (phentermine/topiramate), Xenical (orlistat), and phentermine (single-agent) — all NOT covered under the categorical exclusion.

Patients seeking chronic-weight-management AOMs in Nebraska face cash-pay across all FDA-approved options — our cheapest semaglutide providers ranking and GLP-1 pricing index track current cash rates. Cash-pay alternatives (May 2026 verified):

• NovoCare Wegovy: $199/month new-patient first 2 months; $349/month ongoing pen 0.25–2.4 mg; $399/month Wegovy HD 7.2 mg; $149/month Wegovy oral pill 1.5/4 mg.
• LillyDirect Zepbound vials: $299–$699/month depending on dose; Self Pay Journey Program $449/month for eligible 7.5–15 mg patients.
• LillyDirect Foundayo: $149/month self-pay; $25/month with commercial insurance + savings card.
• Compounded sema/tirz via LegitScript-approved telehealth: typical market $99–$199/month for compounded sema; $149–$249/month for compounded tirz.

6. T2D-indicated GLP-1 pathway

T2D-indicated GLP-1 receptor agonists are covered under the Hypoglycemics-Incretin Mimetics Single PDL class with PA for an FDA-approved diagnosis of type 2 diabetes:

• Preferred: Trulicity (dulaglutide), Victoza (liraglutide), Byetta (exenatide)
• Non-Preferred (with PA): Ozempic (semaglutide), Mounjaro (tirzepatide), Rybelsus (oral semaglutide), Bydureon (exenatide ER)

Off-label prescribing for chronic weight management is NOT reimbursed. A patient seeking Ozempic for weight loss (off-label) cannot obtain coverage without a documented T2D diagnosis. The T2D-CVD overlap (where Ozempic carries an FDA cardiovascular indication for T2D patients) provides a structural workaround for patients with HbA1c ≥ 6.5% + established CVD — they can access semaglutide via Ozempic under the T2D pathway rather than via Wegovy under the MACE carve-out.

7. Heritage Health MCO architecture

Nebraska Medicaid managed care operates under the Heritage Health program. Three MCOs currently contracted:

• Nebraska Total Care (Centene subsidiary)
• UnitedHealthcare Community Plan of Nebraska
• Molina Healthcare of Nebraska (replaced Healthy Blue effective January 1, 2024)

All three MCOs follow the state-level Single PDL and the state PA forms. Pharmacy benefits are essentially uniform across MCOs — the patient's MCO choice does not affect which drugs are covered, only which medical-benefit network is available for physician visits, hospital care, etc. PA submissions for all three MCOs go to Magellan/Prime Therapeutics State Government Solutions (the statewide PBM).

Heritage Health covers approximately 80% of the Nebraska Medicaid population (350–400 thousand enrollees out of ~430,000 total). The dual-eligible and long-term-care populations are not in Heritage Health — they remain in fee-for-service. The expansion population (~90,000 adults) is in Heritage Health.

Patient choice: members can select their MCO at enrollment or annually during open enrollment. Default-assignment applies if no choice is made. MCO transfers outside open enrollment require a qualifying event.

8. Appeals pathway

Nebraska Medicaid appeals run through the Nebraska Department of Health and Human Services Division of Administrative Hearings under Nebraska Revised Statute § 84-901 et seq. (Administrative Procedure Act) and federal regulations at 42 C.F.R. § 431 Subpart E.

Practical denial-recovery path:

1. Contact Magellan/Prime Therapeutics PA help desk (1-866-244-8554) to verify denial rationale. Many denials are documentation deficiencies recoverable via re-submission.
2. Re-submit PA with additional clinical evidence:
   • For Wegovy MACE: ABI report with quantified value; cardiology / vascular / neurology consult note; HbA1c within past 6 months; documented MI, stroke, revascularization, or amputation; age verification.
   • For Wegovy MASH: liver biopsy or FibroScan/MRE report; GI / hepatology consult; 6-month medically-supervised weight-loss-program records (RD notes, BMI trend, dietary modification documentation).
   • For Zepbound OSA: sleep study with AHI/RDI/REI value within past 24 months; BMI ≥ 30 documentation; sleep specialist consult; 70% PAP adherence report from CPAP device download (the printable adherence report from the patient's CPAP/BiPAP device shows hours-per-night usage).
3. If denial stands, file written request for fair hearing with the Nebraska DHHS Division of Administrative Hearings within 90 days of the adverse-action notice.
4. Hearing before an administrative law judge with the right to representation.
5. Final agency decision.
6. Judicial review in Nebraska district court.

Appeal posture by indication:

• Wegovy MACE: appeals strongest when patient meets all FDA-label criteria + Nebraska-specific age 45-74 gate. Patients 75+ should reference FDA-label-no-upper-age-bound + SELECT publication in appeals.
• Wegovy MASH: appeals strongest when 6-month weight-loss-program documentation is complete. If the program is incomplete, the appeal will likely be sustained against the patient (the prerequisite is the gate, not a defensible omission).
• Zepbound OSA: appeals strongest when PAP adherence report (printed from CPAP/BiPAP device) clearly documents 70% adherence over 2+ months. Disputed adherence numbers benefit from a sleep specialist letter contextualizing the data.
• Chronic-weight-management categorical denials: cannot be overturned on appeal — the categorical exclusion is anchored to 42 U.S.C. § 1396r-8(d)(2)(A) and the Pharmacy Provider Manual § 9.2.

9. Nebraska vs. peer states

9.1 Closest peers

• West Virginia — same three carve-outs (Wegovy CV + Wegovy MASH + Zepbound OSA). Key differences: WV has HbA1c ≤ 6.5% gate on Wegovy CV (parallel to NE); WV has T2D step-therapy bridge on Zepbound OSA (NE does not); WV does NOT have the 6-month medically-supervised weight-loss-program MASH prerequisite (NE does); WV does NOT have the 45-74 age gate on Wegovy MACE (NE does). PBM: WV uses Gainwell + WVU Rational Drug Therapy Program (state university school of pharmacy); NE uses Magellan/Prime Therapeutics.
• Arkansas — same three carve-outs operationalized through three separate DUR-Board-approved PA documents. Key differences: AR has ACT 628 § 20-77-154(c) legislative ratification of the exclusion (effective January 1, 2026); AR uses ULM College of Pharmacy / Prime Therapeutics for FFS PA processing; NE has 45-74 age gate on MACE (AR does not); NE has 6-month weight-loss-program prerequisite for MASH (AR does not).
• Oklahoma — four carve-outs (adds Imcivree monogenic-obesity). OK uses OU College of Pharmacy / PMC. NE has more restrictive age + MASH-prerequisite gates.
• Utah — same three indication-permanent carve-outs plus the legislative pilot-program chronic-weight-management coverage (sunsetting 6/30/2026). Utah's Wegovy MACE accepts all adults ≥ 18 (no age cap); Utah requires concurrent guideline-recommended secondary prevention (NE does not require this gate). Utah's Zepbound OSA is the strictest we've documented (in-lab attended PSG + 70% PAP adherence for full 6 months); NE accepts 2-month PAP adherence + sleep study within 24 months (no in-lab requirement). Utah's Wegovy MASH dual-modality requirement (FIB-4 + biopsy/VCTE/ELF/MRE); NE accepts biopsy OR FibroScan/MRE singly.

9.2 Distinctive features summary

Nebraska is the only state we've reviewed with:

• The 45-74 age gate on Wegovy MACE — the narrowest we've documented; mirrors the SELECT trial enrollment age range.
• The 6-month medically-supervised weight-loss-program prerequisite for Wegovy MASH — the most restrictive MASH gate we've documented.
• Bifurcated PA forms across the three indications — UT uses a unified 11-part form; WV combines Wegovy CV+MASH in one document; AR uses three separate DUR-Board-approved documents per indication.

Further reading

• Top GLP-1 insurance-coverage questions on Reddit, answered
• Top compounded vs brand GLP-1 questions on Reddit, answered
• GLP-1 contraindications cheat sheet